European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up

Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia, Torino

Hôpital La Conception, Marseille

Hospital Universitario de A Coruña, A Coruña

Dept of Urology-University Hospital-, Malmo

CHRU Hopital Jean Minjoz, Besançon

Vinzenz Krankenhaus - Department of Urology, Hanover

Department of Urology-Tampere University Hospital-, Tampere

Polyclinique Sévigné, Cesson-Sévigné

Klinikum Braunschweig, Braunschweig

Complejo Hospitalario Regional Virgen Del Rocio-Department Urology, Seville

Clinique Urologique Nantes, Saint-Herblain

Instituto Valenciano de Oncologia, Valencia

Marien Krankenahaus GmbH, Bergisch Gladbach

Hôpital Claude Huriez, Lille

Site Médipole, Cabestany

Centre Hospitalier Universitaire Lyon Sud, Pierre-Bénite

SLK-Kliniken Heilbronn GmbH, Heilbronn

Hôpital Tenon, Paris

Institut Mutualiste Montsouris (IMM), Paris

Hôpital Cochin, Paris

Urologische Gemeinschaftspraxis, Emmendingen

Urologie 24, Nuremberg

Centre Hospitalier Universitaire (CHU), Angers

Catharina Ziekenhuis, Eindhoven

University College London Hospital (UCLH), London

Royal Hallamshire Hospital, Sheffield

CHU Pontchaillou, Rennes

ATURO-Gemeinschaftspraxis für Urologie und Andrologie, Berlin-Wilmersdorf

"Universitätsklinikum Carl Gustav Carus der Technischen Universität", Dresden

Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center, Hamburg

University Hospital Schleswig-Holstein, Kiel

Ludwig-Maximilians-Universität München, Munich

Netherlands Cancer Institute, Amsterdam

Department of Urology-Hospital Clinic, University of Barcelona, Barcelona

Kings College Hospital (KCH), London

Oxford John Radcliffe Hospital Trust, Oxford